We’re innovative thought leaders and determined advocates who partner with visionary organizations to change health care.
We’re innovative thought leaders and determined advocates who partner with visionary organizations to change health care.
We’re innovative thought leaders and determined advocates who partner with visionary organizations to change health care.
Impact Health is a mission-driven health policy and strategic consulting firm dedicated to improving health and well-being for all.
OUR SERVICES
Strategic Planning
Integrate mission-aligned policy expertise and political acumen into planning and executing your goals.
Government Contracting
Track record of success supporting states and municipalities in innovating or launching new programs.
Our proprietary method for tracking, aggregating, and analyzing state policy trends.
If you believe that every American deserves to be healthy and well, contact Impact Health Policy Partners to learn how our expertise can help you achieve your goals.
Policy Hub, managed by Impact Health Policy Partners, is the only comprehensive database of Federal health policy developments, cataloged by over 200 healthcare topics and programs. Regulations, reimbursement, grants, ACA implementation, hearing summaries, CRS Reports, pending legislation – you get it all here, with comprehensive, expert analysis.
Agency Finds Significant Data Gaps in CMS Oversight of Compounded Drugs Under Medicare Part D
The Department of Health and Human Services (HHS) Office of the Inspector General (OIG) released findings from a review of the Centers for Medicare & Medicaid Services’ (CMS) oversight of compounded drugs in Medicare Part D, identifying critical data limitations that undermine program integrity and patient safety. The review found that CMS lacks full visibility into the ingredients of compounded… (Eisen, April 20, 2026) #Medicare Part D, #Opioids, #Prescription Drugs
Agencies Announce Coordinated Actions to Advance Psychedelic Therapies and Behavioral Health Innovation Under Trump Executive Order
The Food and Drug Administration (FDA) and the Advanced Research Projects Agency for Health (ARPA-H) announced new coordinated regulatory and research actions to accelerate the development and access to treatments for serious mental illness. The actions directly build on President Trump’s April 20, 2026 Executive Order directing federal agencies to prioritize innovative therapies for treatment-resistant psychiatric conditions, including psychedelic-based medicines… (Colocho, April 24, 2026) #Food and Drug Administration, #Grants, #Mental and Behavioral Health